SLC5A2 and acromegaly: Given their positive impact on cardiovascular and renal health, in addition to the low risk of hypoglycemia, the use of SGLT2 inhibitors and incretin mimetic drugs should be considered especially in patients with acromegaly at high cardiovascular risk [85].